SGMO (Sangamo) Total Business Assets

SGMO (Sangamo Therapeutics Inc.) - company brandmark

Sangamo Therapeutics (SGMO) is accumulating rare genome modification experts, ensuring zero staff turnover within R&D. Business revenues rely on the implementation of gene therapy, particularly drugs targeting Alzheimer's disease. This chart of total assets, which currently stand at 82.92, complements the profile of a team of medical pioneers forming strategic alliances with global pharmaceutical behemoths.

SGMO - Sangamo Therapeutics Company Total Assets over the range 07/04/2022 - 05/09/2026

Financial and market metric breakdowns for Sangamo (SGMO)

- stock value and consensus price forecast:
Market Price sangamo.com|SGMO - Analyst Consensus Forecast
- business market valuation indicators:
Market Capitalization Sangamo BioSciences|SGMO - Total Company Value
- book capitalization information:
Equity per Share Sangamo Therapeutics|SGMO - Book Capitalization|Market Capitalization to Book Value Ratio sangamo.com|SGMO - Aggregate Company Assets
- debt and liquidity details:
Total Debt to Capital Coefficient Sangamo Therapeutics|SGMO - Long-Term Debt to Capital|Short-Term Debt to Capital Sangamo BioSciences|SGMO - Company Debts|Debt to Book Value Ratio Sangamo BioSciences|SGMO - Company Long-Term Debts|Short-Term Indebtedness Sangamo Therapeutics|Quick Ratio sangamo.com
- earnings and market ratios statistics:
SGMO - Company Net Income
Basic company analysis:sangamo.com
Mass-produced product of Sangamo

Sangamo Therapeutics (SGMO) is developing an innovative "zinc finger" platform for precision genome editing. This indicator reflects the actual value of all company assets, excluding market speculation. By analyzing the history of controlled resources on GURU.Markets, an investor can see a reverse calculation via ROA that combines equity and liabilities. This metric's trend allows for an assessment of the funding efficiency for the development of therapies for Fabry disease and CNS disorders.

Direct competitors

Company Assets Tempus AI, Inc (TEM)|QGEN (Qiagen) - Company Total Assets|Total Business Assets IONS (Ionis Pharmaceuticals, Inc.)|Aggregate Company Assets Repligen Corp. (RGEN)|Avidity Corp - Total Business Assets|Company Total Assets CRSP (CRISPR Therapeutics AG)|Company Total Assets genedx.com WGS|RARE - Aggregate Company Assets|Company Total Asset Base Beam Therapeutics Inc BEAM|SRPT: Company Total Assets|Twist Bioscience Corp (TWST) - Company Total Assets|Aggregate Company Assets 10x Genomics, Inc.|Total Business Assets NTLA (intelliatx.com)|Company Total Assets STOK|BioLife Solutions Inc (BLFS) - Company Balance Sheet Assets|Company Total Assets WVE (Wave Life Sciences Corp)|Company Total Assets Maze Therapeutics Corp MAZE|SION - Aggregate Company Assets|primemedicine.com (PRME) - Cumulative Company Assets|Taysha Gene Therapies, Inc. (TSHA) - Aggregate Company Assets|Company Assets uniQure NV (QURE)|Cumulative Company Assets MGTX|RGNX: Aggregate Asset Value|Cumulative Company Assets SLDB (Solid Biosciences Inc.)|Aggregate Business Assets OCGN|Company Total Assets PACB (PacBio)|Aggregate Asset Value BNTC|Design Pharma - Company Total Assets|Company Assets Rocket Corp|4D Molecular Therapeutics (FDMT) - Aggregate Company Assets|Lexeo Therapeutics, Inc. - Aggregate Asset Value|KRRO (Korro Bio Inc.) - Company Total Assets|Company Total Assets Editas Medicine Inc|Aggregate Company Assets Silence Therapeutics Inc. (SLN)|PRQR: Total Asset Value of Company|Company Total Assets CDXS (Codexis)|Nautilus Biotechnology, Inc. (NAUT) - Company Assets|MGX: Cumulative Company Assets|DTIL - Company Total Assets|GBIO (generationbio.com) - Cumulative Company Assets|BOLD: Aggregate Business Assets|XCUR (Exicure Inc.) - Company Total Assets|Celsion Corporation (IMNN) - Company Total Asset Base|Company Total Assets PHIO|Cumulative Company Assets mustangbio.com MBIO|Aggregate Company Assets TransCode Therapeutics, Inc. RNAZ|Company Total Asset Base Bionano Genomics Inc. (BNGO)|APDN - Aggregate Company Assets|Company Total Asset Base bluebirdbio.com BLUE|IPA: Company Total Assets|Company Balance Sheet Assets Omega Therapeutics Inc OMGA|Aggregate Company Assets Singular Genomics Systems Inc|Cumulative Company Assets Regulus (RGLS)|Aggregate Company Assets Syros Pharmaceuticals (SYRS)|TBIO - Company Assets|Company Total Assets TCON (TRACON Pharmaceuticals, Inc.)|UBX: Total Business Assets